" class="no-js "lang="en-US"> Vertex - Medtech Alert
Friday, May 10, 2024
Vertex | MTA

Vertex

About Vertex

Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, and alpha-1 antitrypsin deficiency. Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune’s Best Workplaces in Biotechnology and Pharmaceuticals and Best Workplaces for Women.

Related Story

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 9 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]

Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis

April 27 2023

Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the FDA

April 3 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced the completion of the rolling Biologics License Applications […]

Vertex and CRISPR Therapeutics Announce Licensing Agreement

March 27 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that they have entered into a new non-exclusive […]